96 related articles for article (PubMed ID: 3020217)
1. Survival in breast cancer related to tumour oestrogen receptor status and immunohistochemical staining for NCRC 11.
Angus B; Napier J; Purvis J; Ellis IO; Hawkins RA; Carpenter F; Horne CH
J Pathol; 1986 Aug; 149(4):301-6. PubMed ID: 3020217
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in breast cancer: immunohistochemical staining for SP1 and NCRC 11 related to survival, tumour epidermal growth factor receptor and oestrogen receptor status.
Wright C; Angus B; Napier J; Wetherall M; Udagawa Y; Sainsbury JR; Johnston S; Carpenter F; Horne CH
J Pathol; 1987 Dec; 153(4):325-31. PubMed ID: 2828590
[TBL] [Abstract][Full Text] [Related]
3. Oestrogen receptor staining of paraffin-embedded breast carcinomas following short fixation in formalin: a comparison with cytosolic and frozen section receptor analyses.
Raymond WA; Leong AS
J Pathol; 1990 Apr; 160(4):295-303. PubMed ID: 2162939
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
Francis G; Beadle G; Thomas S; Mengersen K; Stein S
Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
[TBL] [Abstract][Full Text] [Related]
5. Tumour cellularity, oestrogen receptors and prognosis in breast cancer.
Black R; Prescott R; Bers K; Hawkins A; Stewart H; Forrest P
Clin Oncol; 1983 Dec; 9(4):311-8. PubMed ID: 6661854
[TBL] [Abstract][Full Text] [Related]
6. Oestrogen receptors revisited: long-term follow up of over five thousand breast cancer patients.
Hähnel R; Spilsbury K
ANZ J Surg; 2004 Nov; 74(11):957-60. PubMed ID: 15550082
[TBL] [Abstract][Full Text] [Related]
7. Relationships between oestrogen receptor,epidermal growth factor receptor, ER-D5, and P24 oestrogen regulated protein in human breast cancer.
Horne GM; Angus B; Wright C; Needham G; Nicholson S; Harris AL; Innes B; Horne CH
J Pathol; 1988 Jun; 155(2):143-50. PubMed ID: 3292735
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11.
Dykins R; Corbett IP; Henry JA; Wright C; Yuan J; Hennessy C; Lennard TJ; Angus B; Horne CH
J Pathol; 1991 Feb; 163(2):105-10. PubMed ID: 1673154
[TBL] [Abstract][Full Text] [Related]
9. C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein.
Looi LM; Cheah PL
Malays J Pathol; 1998 Jun; 20(1):19-23. PubMed ID: 10879259
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of the prognostic significance of vascular endothelial growth factor in node positive primary breast carcinoma.
MacConmara M; O'Hanlon DM; Kiely MJ; Connolly Y; Jeffers M; Keane FB
Int J Oncol; 2002 Apr; 20(4):717-21. PubMed ID: 11894115
[TBL] [Abstract][Full Text] [Related]
11. Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistometry of the most positive tumour focus. A prospective follow-up study on breast cancer using antibodies against MIB-1, PCNA, ER, and PR.
Biesterfeld S; Klüppel D; Koch R; Schneider S; Steinhagen G; Mihalcea AM; Schröder W
J Pathol; 1998 May; 185(1):25-31. PubMed ID: 9713356
[TBL] [Abstract][Full Text] [Related]
12. The relationship between growth fractions and oestrogen receptors in human breast carcinoma, as determined by immunohistochemical staining.
Raymond WA; Leong AS
J Pathol; 1989 Jul; 158(3):203-11. PubMed ID: 2769481
[TBL] [Abstract][Full Text] [Related]
13. Oestrogen and progesterone receptor status of individual foci in multifocal invasive ductal breast cancer.
Garimella V; Long ED; O'Kane SL; Drew PJ; Cawkwell L
Acta Oncol; 2007; 46(2):204-7. PubMed ID: 17453370
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.
Cheang MC; Treaba DO; Speers CH; Olivotto IA; Bajdik CD; Chia SK; Goldstein LC; Gelmon KA; Huntsman D; Gilks CB; Nielsen TO; Gown AM
J Clin Oncol; 2006 Dec; 24(36):5637-44. PubMed ID: 17116944
[TBL] [Abstract][Full Text] [Related]
15. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
Elledge RM; Green S; Ciocca D; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; O'Sullivan J; Martino S; Osborne CK
Clin Cancer Res; 1998 Jan; 4(1):7-12. PubMed ID: 9516946
[TBL] [Abstract][Full Text] [Related]
16. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer.
Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; van de Vijver MJ
Eur J Surg Oncol; 1999 Aug; 25(4):356-63. PubMed ID: 10419704
[TBL] [Abstract][Full Text] [Related]
17. Studies on p53 immunolocalisation in breast cancer and its prognostic significance.
Meenakshi A; Manoharan V
Hum Antibodies; 1999; 9(3):171-6. PubMed ID: 10690631
[TBL] [Abstract][Full Text] [Related]
18. LEA.135 expression: its comparison with other prognostic biomarkers for patients with primary breast carcinoma.
Liu D; Baltayan A; Naritoku WY; Barr NJ; Young LL; Chaiwun B; Tsao-Wei DD; Groshen SL; Taylor CR; Torloni H; Neville AM; Cote RJ; Imam SA
Anticancer Res; 2000; 20(3A):1451-61. PubMed ID: 10928056
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of immunoperoxidase staining with monoclonal antibodies NCRC-11 and 3E1.2 in breast cancer.
Muir IM; Reed RG; Stacker SA; Alexander AI; McKenzie IF; Bennett RC
Br J Cancer; 1991 Jul; 64(1):124-7. PubMed ID: 1854611
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of the usefulness of primary tumour expression of MCA and CA15-3 as prognostic indicators in breast carcinoma.
Byrne J; Horgan PG; England S; Callaghan J; Given HF
Eur J Surg Oncol; 1992 Jun; 18(3):230-4. PubMed ID: 1607033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
